S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
OTCMKTS:EMMA

Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

$0.13
+0.02 (+18.18%)
(As of 02/26/2024 ET)
Today's Range
$0.11
$0.13
50-Day Range
$0.07
$0.13
52-Week Range
$0.05
$0.42
Volume
14,661 shs
Average Volume
24,075 shs
Market Capitalization
$8.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

EMMA stock logo

About Emmaus Life Sciences Stock (OTCMKTS:EMMA)

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

EMMA Stock Price History

EMMA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Emmaus Life Sciences (OTCMKTS:EMMA) Stock Price Up 51.7%
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Emmaus Life Sciences Reports Q3 2023 Financial Results
See More Headlines
Receive EMMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/26/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:EMMA
Employees
54
Year Founded
N/A

Profitability

Net Income
$-10,620,000.00
Pretax Margin
-16.42%

Debt

Sales & Book Value

Annual Sales
$18.39 million
Book Value
($0.69) per share

Miscellaneous

Free Float
40,200,000
Market Cap
$8.04 million
Optionable
Not Optionable
Beta
1.64
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Willis C. Lee M.S. (Age 64)
    Co-President, COO & Chairman of the Board
    Comp: $240k
  • Mr. Yasushi Nagasaki CPA (Age 57)
    CPA, Chief Financial Officer
    Comp: $250k
  • Mr. George Sekulich (Age 58)
    Co-President, Chief Commercial Officer & Director
  • Mr. Dale E. Short J.D.
    Legal Consultant & Corporate Secretary
  • Dr. Charles W. Stark Pharm.D (Age 69)
    Pharm.D., Senior Vice President of Medical Affairs, Clinical, Regulatory
  • Mr. Kurt H. Kruger M.B.A. (Age 69)
    M.S., Consultant
    Comp: $300.02k














EMMA Stock Analysis - Frequently Asked Questions

How have EMMA shares performed in 2024?

Emmaus Life Sciences' stock was trading at $0.1001 at the start of the year. Since then, EMMA stock has increased by 29.9% and is now trading at $0.13.
View the best growth stocks for 2024 here
.

Are investors shorting Emmaus Life Sciences?

Emmaus Life Sciences saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 4,100 shares, a drop of 6.8% from the December 31st total of 4,400 shares. Based on an average daily trading volume, of 9,500 shares, the days-to-cover ratio is presently 0.4 days.
View Emmaus Life Sciences' Short Interest
.

When is Emmaus Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our EMMA earnings forecast
.

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EMMA) was last updated on 2/27/2024 by MarketBeat.com Staff